Population Pharmacokinetic Modelling for Nifedipine to Evaluate the Effect of Parathyroid Hormone on CYP3A in Patients with Chronic Kidney Disease
Chengxiao Fu,1,2,* Qi Pei,3,* Wu Liang,4 Bo Yang,2 Wei Li,5 Jun Liu,5 Hongyi Tan,1,4 Chengxian Guo,1,4 Hao Zhang,5 Guoping Yang1,4 1Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 2The First Affiliated Hosp...
Main Authors: | Fu C, Pei Q, Liang W, Yang B, Li W, Liu J, Tan H, Guo C, Zhang H, Yang G |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-07-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/population-pharmacokinetic-modelling-for-nifedipine-to-evaluate-the-ef-peer-reviewed-fulltext-article-DDDT |
Similar Items
-
Effect of Gut Microbiota on the Pharmacokinetics of Nifedipine in Spontaneously Hypertensive Rats
by: Rong Zhou, et al.
Published: (2023-08-01) -
Panax notoginseng saponins increases the blood concentration of nifedipine by inhibiting CYP3A4 enzyme through PXR- and CAR-Mediated pathway
by: Qiu-Hong Li, et al.
Published: (2021-01-01) -
A Liposomal Formulation for Improving Solubility and Oral Bioavailability of Nifedipine
by: Ye Bi, et al.
Published: (2020-01-01) -
Recent Developments in Parathyroid Hormone Type 1 Receptor and Kidney Disease
by: YAN Peng, SONG Jianling, FANG Xiangdong
Published: (2023-04-01) -
Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors
by: Zhu YT, et al.
Published: (2020-05-01)